Alteon to Present at Bio Emerging Company Investor Forum Thursday, October 14, 2004
October 07 2004 - 10:00AM
PR Newswire (US)
Alteon to Present at Bio Emerging Company Investor Forum Thursday,
October 14, 2004 - Presentation to be Webcast - PARSIPPANY, N.J.,
Oct. 7 /PRNewswire/ -- Alteon Inc. (AMEX:ALT) announced today that
it has been selected for a company presentation at the BIO Emerging
Company Investor Forum in San Francisco. Kenneth I. Moch, Alteon's
President and Chief Executive Officer, is scheduled to present at
3:00 p.m., Pacific Time, on Thursday, October 14, 2004. The live
presentation will be webcast and will be accessible at the investor
relations section of Alteon's corporate website,
http://www.alteon.com/, where it also will be archived. Note to
Conference Attendees: Alteon has made time available for one-on-one
meetings. Please contact Susan Pietropaolo, , if you are interested
in setting up a meeting. Alternatively, you can request a meeting
through the BIO one-on-one meeting system. About Alteon Alteon is
developing several new classes of drugs that reverse or slow down
diseases of aging and complications of diabetes. These compounds
have an impact on a fundamental pathological process caused by
protein-glucose complexes called Advanced Glycation End-products
(A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss
of flexibility and function in body tissues, organs and vessels and
have been shown to be a causative factor in many age-related
diseases and diabetic complications. Alteon has created a library
of novel classes of compounds targeting the A.G.E. Pathway.
Alteon's lead compound alagebrium chloride (formerly ALT-711), the
only A.G.E. Crosslink Breaker in advanced human testing, has
demonstrated safety and efficacy in several Phase 2 trials and is
actively being developed for systolic hypertension and heart
failure. Ongoing clinical trials include SPECTRA (Systolic Pressure
Efficacy and Safety Trial of Alagebrium) and PEDESTAL (Patients
with Impaired Ejection Fraction and Diastolic Dysfunction: Efficacy
and Safety Trial of ALagebrium), as well as a third trial exploring
mechanism of action in endothelial dysfunction. For more
information on Alteon, visit the company's website at
http://www.alteon.com/. Any statements contained in this press
release that relate to future plans, events or performance are
forward-looking statements that involve risks and uncertainties
including, but not limited to, those relating to technology and
product development (including the possibility that early clinical
trial results may not be predictive of results that will be
obtained in large-scale testing or that any clinical trials will
not demonstrate sufficient safety and efficacy to obtain requisite
approvals or will not result in marketable products), regulatory
approval processes, intellectual property rights and litigation,
competitive products, ability to obtain financing, and other risks
identified in Alteon's filings with the Securities and Exchange
Commission. The information contained in this press release is
accurate as of the date indicated. Actual results, events or
performance may differ materially. Alteon undertakes no obligation
to publicly release the result of any revision to these
forward-looking statements that may be made to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M.
Pietropaolo, Director, Corporate Communications & Investor
Relations, Web site: http://www.alteonpharma.com/
Copyright
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ishares Diversified Alternatives Trust (AMEX:ALT)
Historical Stock Chart
From Jul 2023 to Jul 2024